Perspective for prophylaxis and treatment of cervical cancer

An immunological approach

Marjorie Jenkins, Maurizio Chiriva-Internati, Leonardo Mirandola, Catherine Tonroy, Sean S. Tedjarati, Nicole Davis, Nicholas D'Cunha, Lukman Tijani, Fred Hardwick, Diane Nguyen, W. Martin Kast, Everardo Cobos

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.

Original languageEnglish (US)
Pages (from-to)3-21
Number of pages19
JournalInternational Reviews of Immunology
Volume31
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Papillomaviridae
Uterine Cervical Neoplasms
Papillomavirus Vaccines
Active Immunotherapy
Virus Diseases
Therapeutics
Immunotherapy
Vaccines
Morbidity
Mortality
Neoplasms

Keywords

  • Cancer vaccines
  • Gynecologic oncology
  • HPV
  • Immunotherapy
  • Tumor prevention

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Jenkins, M., Chiriva-Internati, M., Mirandola, L., Tonroy, C., Tedjarati, S. S., Davis, N., ... Cobos, E. (2012). Perspective for prophylaxis and treatment of cervical cancer: An immunological approach. International Reviews of Immunology, 31(1), 3-21. https://doi.org/10.3109/08830185.2011.637254

Perspective for prophylaxis and treatment of cervical cancer : An immunological approach. / Jenkins, Marjorie; Chiriva-Internati, Maurizio; Mirandola, Leonardo; Tonroy, Catherine; Tedjarati, Sean S.; Davis, Nicole; D'Cunha, Nicholas; Tijani, Lukman; Hardwick, Fred; Nguyen, Diane; Kast, W. Martin; Cobos, Everardo.

In: International Reviews of Immunology, Vol. 31, No. 1, 02.2012, p. 3-21.

Research output: Contribution to journalArticle

Jenkins, M, Chiriva-Internati, M, Mirandola, L, Tonroy, C, Tedjarati, SS, Davis, N, D'Cunha, N, Tijani, L, Hardwick, F, Nguyen, D, Kast, WM & Cobos, E 2012, 'Perspective for prophylaxis and treatment of cervical cancer: An immunological approach', International Reviews of Immunology, vol. 31, no. 1, pp. 3-21. https://doi.org/10.3109/08830185.2011.637254
Jenkins, Marjorie ; Chiriva-Internati, Maurizio ; Mirandola, Leonardo ; Tonroy, Catherine ; Tedjarati, Sean S. ; Davis, Nicole ; D'Cunha, Nicholas ; Tijani, Lukman ; Hardwick, Fred ; Nguyen, Diane ; Kast, W. Martin ; Cobos, Everardo. / Perspective for prophylaxis and treatment of cervical cancer : An immunological approach. In: International Reviews of Immunology. 2012 ; Vol. 31, No. 1. pp. 3-21.
@article{3c7a13127d46441b9de39162dbc96b63,
title = "Perspective for prophylaxis and treatment of cervical cancer: An immunological approach",
abstract = "As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.",
keywords = "Cancer vaccines, Gynecologic oncology, HPV, Immunotherapy, Tumor prevention",
author = "Marjorie Jenkins and Maurizio Chiriva-Internati and Leonardo Mirandola and Catherine Tonroy and Tedjarati, {Sean S.} and Nicole Davis and Nicholas D'Cunha and Lukman Tijani and Fred Hardwick and Diane Nguyen and Kast, {W. Martin} and Everardo Cobos",
year = "2012",
month = "2",
doi = "10.3109/08830185.2011.637254",
language = "English (US)",
volume = "31",
pages = "3--21",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Perspective for prophylaxis and treatment of cervical cancer

T2 - An immunological approach

AU - Jenkins, Marjorie

AU - Chiriva-Internati, Maurizio

AU - Mirandola, Leonardo

AU - Tonroy, Catherine

AU - Tedjarati, Sean S.

AU - Davis, Nicole

AU - D'Cunha, Nicholas

AU - Tijani, Lukman

AU - Hardwick, Fred

AU - Nguyen, Diane

AU - Kast, W. Martin

AU - Cobos, Everardo

PY - 2012/2

Y1 - 2012/2

N2 - As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.

AB - As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.

KW - Cancer vaccines

KW - Gynecologic oncology

KW - HPV

KW - Immunotherapy

KW - Tumor prevention

UR - http://www.scopus.com/inward/record.url?scp=84856120727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856120727&partnerID=8YFLogxK

U2 - 10.3109/08830185.2011.637254

DO - 10.3109/08830185.2011.637254

M3 - Article

VL - 31

SP - 3

EP - 21

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 1

ER -